• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

More leeway for drug price negotiation

Article

One important, but less-noticed, provision in the Medicare program exempts Medicare drug plans from the "best price" policy that limits the ability of health plans and PBMs to negotiate low drug prices. Now the Bush administration is looking to drop the best price requirement for all drug purchasers.

Washington, D.C. - One important, but less-noticed, provision in the Medicare program exempts Medicare drug plans from the "best price" policy that limits the ability of health plans and PBMs to negotiate low drug prices. Now the Bush administration is looking to drop the best price requirement for all drug purchasers.

Congress added "best price" to Medicaid a decade ago to encourage pharmaceutical marketers to give Medicaid their very lowest prices. Manufacturers agreed to pay rebates to state Medicaid programs of about 15% in return for a limit on offering even lower discounts to other customers. The feds subsequently provided an exemption from best price for drugs purchased by the Veterans Administration and other government agencies, including the new Medicare program. But HMOs and hospitals have complained for years that best price prevents them from negotiating low prices for their formularies. CMS administrator Dr. Mark McClellan evidently agrees and has proposed switching to a flat rebate formula for everyone. The aim is not to curb Medicaid prescription drug spending, but to help reduce costs for the broader healthcare system.

-Jill Wechsler

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Related Content
© 2024 MJH Life Sciences

All rights reserved.